Phase 3b trial in 485 adults with type 2 diabetes on oral drugs: once-weekly IcoSema cut HbA1c more than daily glargine U100 at 40 weeks (-3.32 vs -2.44 points; ETD -0.88), with weight -0.79 vs +3.81 kg and less hypoglycaemia; GI events were commonest.
RCTn = 485
Ji et al. Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial